Abbott's Q3: Strong Devices, China Struggles, Can it Bounce?
Update: 2025-10-22
Description
Abbott's Q3 Results: A Mixed Bag! Despite matching Wall Street's expectations with $11.4B in revenue, shares dipped 4%. Medical devices shined, but diagnostics in China struggled. CEO Robert Ford highlighted $5B in sales from new products, yet competition in pediatric nutrition persists. Analysts grilled execs on China growth and diabetes tech. Can Abbott rebound by scaling new devices and fixing weak spots? Investors are watching closely!
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
